As Dame Emma Walmsley stood up to deliver GSK’s latest set of results last month, she was brimming with confidence. This was “another excellent” period, she said, with sales and profits at the company booming.
GSK shares have taken a hit in recent weeks due to Zantac uncertainty. Here, Edward Sheldon looks at whether they’re now cheap. The post Are GSK shares a bargain after falling 11%? appeared first on The Motley Fool UK.
GSK has launched an appeal against the Delaware Superior Court's recent so-called Daubert ruling.